Owing to the propensity for visual loss, immunosuppressive treatment in the form of systemic and/or local therapy is often required for the management of noninfective intermediate and posterior ...

September 28, 2010 — The US Food and Drug Administration (FDA) has approved a dexamethasone 0.7 mg intravitreal implant (Ozurdex; Allergan, Inc) for the treatment of noninfectious ocular inflammation ...

This page lists all known medications that could potentially lead to 'Posterior uveitis' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

An estimated five to ten percent of blindness worldwide is caused by the rare inflammatory eye disease uveitis. Posterior uveitis in particular is often associated with severe disease progression and ...

Early IOP safety data are encouraging for Medidur, a treatment for posterior uveitis in phase 3 trial, pSivida announced in a press release. At 3 months, only 4% more study eyes demonstrated elevated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A phase 3 trial of Durasert 3-year ...

Objectives There is evidence that pars plana vitrectomy (PPV) has a beneficial effect on the clinical course of chronic endogenous posterior uveitis (EPU) possibly by physically removing any resident ...

An open-label clinical trial including seven patients (12 eyes) with posterior uveitis refractory to conventional treatment regimens with corticosteroids and at least one immunosuppressive agent.

Twenty-one patients with syphilitic posterior uveitis were investigated retrospectively to study the disease spectrum, associations with neurosyphilis, and therapeutic implications. Ophthalmologic ...

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive ...

ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners ...

ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners ...